{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-23-000070","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.121752+00:00","generated_at":"2026-06-09T04:31:09.183566+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Selecta transitions SEL-212 manufacturing to Sobi; CMO goes part-time","bullets":["Selecta granted Sobi exclusive license to manufacture ImmTOR for SEL-212; Sobi assumes all manufacturing and commercial supply.","15 Selecta employees expected to become Sobi employees; CMO Peter Traber moves to part-time at Selecta and consultant to Sobi.","Selecta retains eligibility for up to $615M in remaining milestones and tiered double-digit royalties on SEL-212 net sales.","BLA submission for SEL-212 on track for first half of 2024; peak U.S. sales potential estimated at >$700M.","Dr. Traber's base salary reduced to $250,000; severance benefits tied to pre-amendment salary in certain termination scenarios."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-23-000070","json":"https://secwatch.observer/filing/0001453687-23-000070.json","markdown":"https://secwatch.observer/filing/0001453687-23-000070.md","text":"https://secwatch.observer/filing/0001453687-23-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000070/0001453687-23-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000070/selb-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:31:09.183566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c690e8d53e","claim":"Peter Traber changed role as Chief Medical Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"Peter Traber, the Company’s Chief Medical Officer, has agreed to serve as a consultant to Sobi and move to part-time status as the Company’s Chief Medical Officer, each effective as of November 6, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000070/0001453687-23-000070-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"move to part-time status"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"c5f7e967ce0bf253632b199db352da94c9181ae6","claim":"Cartesian Therapeutics, Inc. amended License and Development Agreement with Swedish Orphan Biovitrum AB (publ.) valued at The Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi’s (effective 2023-10-31).","evidence_excerpt":"On October 31, 2023, Selecta Biosciences, Inc. (the “Company”) and Swedish Orphan Biovitrum AB (publ.) (“Sobi”) entered into Amendment No. 1 (the “Amendment”) to the License and Development Agreement (as so amended, the “Agreement”) by and between the Company and Sobi. Pursuant to the Amendment, the Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi’s development of SEL-212 under the Agreement and is transferring certain contracts and manufacturing equipment to Sobi. Additionally, in connection with entry into the Amendment, Sobi agreed to make employment offers to certain of the Company’s employees engaged in ImmTOR manufacturing activities on or prior to a specified date, and the Company agreed not to terminate the employment of such employees prior to such specified date.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000070/0001453687-23-000070-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Swedish Orphan Biovitrum AB (publ.)"},{"label":"Value","value":"The Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi’s"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}